BACKGROUND:Postmenopausal hormone therapy has been examined extensively in relation to cardiovascular disease. However, research relating serum levels of sex hormones to cardiovascular disease is sparse, and the results are inconclusive. METHODS: We measured sex hormones in longitudinally collected samples of 180 postmenopausal women, 91 randomized to 17beta-estradiol and 89 toplacebo, in the Estrogen in the Prevention of Atherosclerosis Trial. Repeated measures of sex hormone levels were tested for an association with carotid artery intima-media thickness (CIMT), which was also assessed longitudinally over 2 yr. RESULTS: In all women, changes in serum estrone (P = 0.02), total estradiol (P = 0.01), free estradiol (P = 0.02), and SHBG (P = 0.005) were significantly inversely associated with CIMT progression, controlling for age and body mass index. All the estrogen compounds and SHBG were significantly inversely related with low-density lipoprotein cholesterol and positively associated with high-density lipoprotein cholesterol (all P < 0.0001), whereas free testosterone was positively related with low-density lipoprotein cholesterol and inversely associated with high-density lipoprotein cholesterol (P < 0.003). Despite an increase in serum-free estradiol with estradiol therapy, women with unchanged SHBG and free testosterone levels had an average (se) progression in CIMT of 8.53 (4.72) microm/yr, whereas women with increased free estradiol and SHBG and decreased free testosterone had the largest reduction in CIMT progression [-5.45 (2.77) microm/yr; trend P = 0.03]. CONCLUSION:Estrogen and SHBG are associated with reduced subclinical atherosclerosis progression in healthy postmenopausal women. These associations are partially mediated by their beneficial effects on lipids. Among women taking estradiol, the most beneficial hormone profile for CIMT progression was increased free estradiol and SHBG with concomitant decreased free testosterone.
RCT Entities:
BACKGROUND: Postmenopausal hormone therapy has been examined extensively in relation to cardiovascular disease. However, research relating serum levels of sex hormones to cardiovascular disease is sparse, and the results are inconclusive. METHODS: We measured sex hormones in longitudinally collected samples of 180 postmenopausal women, 91 randomized to 17beta-estradiol and 89 to placebo, in the Estrogen in the Prevention of Atherosclerosis Trial. Repeated measures of sex hormone levels were tested for an association with carotid artery intima-media thickness (CIMT), which was also assessed longitudinally over 2 yr. RESULTS: In all women, changes in serum estrone (P = 0.02), total estradiol (P = 0.01), free estradiol (P = 0.02), and SHBG (P = 0.005) were significantly inversely associated with CIMT progression, controlling for age and body mass index. All the estrogen compounds and SHBG were significantly inversely related with low-density lipoprotein cholesterol and positively associated with high-density lipoprotein cholesterol (all P < 0.0001), whereas free testosterone was positively related with low-density lipoprotein cholesterol and inversely associated with high-density lipoprotein cholesterol (P < 0.003). Despite an increase in serum-free estradiol with estradiol therapy, women with unchanged SHBG and free testosterone levels had an average (se) progression in CIMT of 8.53 (4.72) microm/yr, whereas women with increased free estradiol and SHBG and decreased free testosterone had the largest reduction in CIMT progression [-5.45 (2.77) microm/yr; trend P = 0.03]. CONCLUSION: Estrogen and SHBG are associated with reduced subclinical atherosclerosis progression in healthy postmenopausal women. These associations are partially mediated by their beneficial effects on lipids. Among women taking estradiol, the most beneficial hormone profile for CIMT progression was increased free estradiol and SHBG with concomitant decreased free testosterone.
Authors: H N Hodis; W J Mack; R A Lobo; D Shoupe; A Sevanian; P R Mahrer; R H Selzer; C R Liu Cr; C H Liu Ch; S P Azen Journal: Ann Intern Med Date: 2001-12-04 Impact factor: 25.391
Authors: Sherita Hill Golden; Ann Maguire; Jingzhong Ding; J R Crouse; Jane A Cauley; Howard Zacur; Moyses Szklo Journal: Am J Epidemiol Date: 2002-03-01 Impact factor: 4.897
Authors: Holger Reinecke; Janina Bogdanski; Anne Woltering; G Breithardt; Gerd Assmann; Sebastian Kerber; Arnold von Eckardstein Journal: Am J Cardiol Date: 2002-08-15 Impact factor: 2.778
Authors: Kathryn M Rexrode; JoAnn E Manson; I-Min Lee; Paul M Ridker; Patrick M Sluss; Nancy R Cook; Julie E Buring Journal: Circulation Date: 2003-09-15 Impact factor: 29.690
Authors: C Noel Bairey Merz; B Delia Johnson; Barry L Sharaf; Vera Bittner; Sarah L Berga; Glenn D Braunstein; T Keta Hodgson; Karen A Matthews; Carl J Pepine; Steven E Reis; Nathaniel Reichek; William J Rogers; Gerald M Pohost; Sheryl F Kelsey; George Sopko Journal: J Am Coll Cardiol Date: 2003-02-05 Impact factor: 24.094
Authors: Alka M Kanaya; David Herrington; Eric Vittinghoff; Feng Lin; Deborah Grady; Vera Bittner; Jane A Cauley; Elizabeth Barrett-Connor Journal: Ann Intern Med Date: 2003-01-07 Impact factor: 25.391
Authors: Robin Haring; Thomas G Travison; Shalender Bhasin; Ramachandran S Vasan; Henri Wallaschofski; Maithili N Davda; Andrea Coviello; Joanne M Murabito Journal: J Clin Endocrinol Metab Date: 2011-09-21 Impact factor: 5.958
Authors: B Delia Johnson; Kathleen M Dwyer; Frank Z Stanczyk; Vera Bittner; Sarah L Berga; Glenn D Braunstein; Ricardo Azziz; YuChing Yang; Georgina E Hale; C Noel Bairey Merz Journal: J Clin Endocrinol Metab Date: 2010-06-16 Impact factor: 5.958
Authors: Virginia M Miller; Brian D Lahr; Kent R Bailey; Howard N Hodis; Sharon L Mulvagh; Muthuvel Jayachandran Journal: Atherosclerosis Date: 2015-12-28 Impact factor: 5.162
Authors: Samar R El Khoudary; Nanette Santoro; Hsiang-Yu Chen; Ping G Tepper; Maria M Brooks; Rebecca C Thurston; Imke Janssen; Sioban D Harlow; Emma Barinas-Mitchell; Faith Selzer; Carol A Derby; Elizabeth A Jackson; Daniel McConnell; Karen A Matthews Journal: Eur J Prev Cardiol Date: 2015-09-18 Impact factor: 7.804
Authors: Intira Sriprasert; Howard N Hodis; Roksana Karim; Frank Z Stanczyk; Donna Shoupe; Victor W Henderson; Wendy J Mack Journal: J Clin Endocrinol Metab Date: 2019-02-01 Impact factor: 5.958